CA2364253A1 - Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase - Google Patents

Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase Download PDF

Info

Publication number
CA2364253A1
CA2364253A1 CA002364253A CA2364253A CA2364253A1 CA 2364253 A1 CA2364253 A1 CA 2364253A1 CA 002364253 A CA002364253 A CA 002364253A CA 2364253 A CA2364253 A CA 2364253A CA 2364253 A1 CA2364253 A1 CA 2364253A1
Authority
CA
Canada
Prior art keywords
compound
dihydroxy open
open acid
simvastatin
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002364253A
Other languages
English (en)
Inventor
Richard D. Tillyer
Paul J. Reider
Edward J. J. Grabowski
Feng Xu
Jose M. Vega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2364253A1 publication Critical patent/CA2364253A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des procédés et des compositions pharmaceutiques pour l'inhibition de la HMG-CoA réductase, ainsi que pour le traitement et/ou la réduction du risque de maladies et d'états modifiés par l'inhibition de la HMG-CoA réductase. Lesdits procédés consistent à administrer par voie orale une dose efficace au plan thérapeutique d'un composé choisi parmi une statine d'acide ouvert en dihydroxy, un sel acceptable au plan pharmaceutique ou un ester, dans une forme galénique à effet retard, à un patient ayant besoin dudit traitement, la libération du composé par la forme galénique étant retardée jusqu'à ce que la forme galénique soit passée dans l'estomac.
CA002364253A 1999-03-08 2000-02-02 Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase Abandoned CA2364253A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12322799P 1999-03-08 1999-03-08
US60/123,227 1999-03-08
US26474499A 1999-03-09 1999-03-09
US09/264,744 1999-03-09
PCT/US2000/002626 WO2000053173A1 (fr) 1999-03-08 2000-02-02 Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase

Publications (1)

Publication Number Publication Date
CA2364253A1 true CA2364253A1 (fr) 2000-09-14

Family

ID=26821357

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002364253A Abandoned CA2364253A1 (fr) 1999-03-08 2000-02-02 Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase

Country Status (9)

Country Link
EP (1) EP1161236A1 (fr)
JP (2) JP2002538202A (fr)
AR (1) AR022856A1 (fr)
AU (1) AU2866400A (fr)
CA (1) CA2364253A1 (fr)
CO (1) CO5150193A1 (fr)
PE (1) PE20001559A1 (fr)
SV (1) SV2002000036A (fr)
WO (1) WO2000053173A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523948A (ja) * 1999-11-04 2003-08-12 アンドルクス コーポレーション アミロイドβ前駆体障害の治療法
WO2002020457A1 (fr) * 2000-09-06 2002-03-14 Merck & Co., Inc. Sel d'acide ouvert dihydroxy de simvastatine
JPWO2002030425A1 (ja) * 2000-10-12 2004-02-19 日産化学工業株式会社 糖尿病合併症予防・治療剤
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
HUP0500616A3 (en) * 2001-08-16 2011-07-28 Teva Pharma Processes for preparing calcium salt forms of statins
EP1429756B1 (fr) 2001-09-21 2006-11-22 Schering Corporation Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CA2476538C (fr) * 2002-01-09 2012-07-17 Crucell Holland B.V. Utilisation de l'erythropoietine pour le traitement preventif ou curatif de l'insuffisance cardiaque
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
US7390504B2 (en) * 2003-11-07 2008-06-24 Jj Pharma, Inc. HDL-boosting combination therapy complexes
US10208351B2 (en) 2013-10-18 2019-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) RNY-derived small RNAs as biomarkers for atherosclerosis-related disorders
KR20240157129A (ko) 2017-05-15 2024-10-31 유니버시티 오브 신시내티 심바스타틴의 하나 이상의 대사 산물들을 직접 투여함으로써 무혈관성 연골 조직의 결함들을 치료하기 위한 조성물들 및 방법들
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
DE69625046T2 (de) * 1995-12-22 2003-04-10 Kowa Co., Ltd. Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor

Also Published As

Publication number Publication date
CO5150193A1 (es) 2002-04-29
SV2002000036A (es) 2002-02-05
PE20001559A1 (es) 2001-01-16
WO2000053173A1 (fr) 2000-09-14
JP2002538202A (ja) 2002-11-12
AU2866400A (en) 2000-09-28
AR022856A1 (es) 2002-09-04
JP2000256191A (ja) 2000-09-19
EP1161236A1 (fr) 2001-12-12

Similar Documents

Publication Publication Date Title
US6569461B1 (en) Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
AU764048B2 (en) Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
WO2000053173A1 (fr) Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase
EP1036563A1 (fr) Formulations retard a usage oral de simvastatine sous forme ouverte d'acide dihydroxy, de ses sels ou de ses esters
AU2002310409C1 (en) Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
CN1867322B (zh) 结晶形式的γ-氨基丁酸类似物
AU2010221167B2 (en) Oral dosage forms having a high loading of a gabapentin prodrug
HRP20030104A2 (en) Therapeutic combination
US20030176501A1 (en) Dihydroxy open-acid salt of simvastatin
US12208167B1 (en) Coated tablets for pH-dependent release of benzgalantamine
HK1029758A (en) Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
EP2024316B9 (fr) Forme cristalline du leucotriene b4
HK1029786A (en) Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
US9969674B2 (en) MMF-derivatives of ethyleneglycols
US11795180B2 (en) Formulation of a pan-JAK inhibitor
WO2025147235A1 (fr) Composition d'association à dose fixe d'obicetrapib et d'ézétimibe
JP2008162949A (ja) チアゾリジンジオン化合物を含有する糖尿病治療薬
CN102976996A (zh) 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用

Legal Events

Date Code Title Description
FZDE Dead